Categories Earnings, Health Care

AMAG Pharmaceuticals (AMAG) Q4 2019 Earnings Snapshot

— AMAG Pharmaceuticals (NASDAQ: AMAG) reported a net loss of $199.9 million or $5.89 per share for the fourth quarter of 2019 vs. $0.36 per share loss expected.

— During the fourth quarter, the company recorded impairment charges of $155 million.

Earnings Update by AlphaStreet

— Revenue increased to $89.7 million from $88.1 million last year vs. $88.39 million expected.

— For fiscal 2020, AMAG expects revenue to be between $230 million and $280 million. Non-GAAP adjusted EBITDA is expected to be in the range of $20 million to $50 million.

— 2020 key priorities include completing CEO transition, divest Intrarosa and Vyleesi, drive continued Feraheme growth and work with the FDA to maintain patient access to Makena.

— AMAG also announced today that its Chief Medical Officer Julie Krop will be leaving the company with effect from March 31, 2020. The Board has initiated the search for a permanent CMO.

— AMAG stock had retreated 24% in the past three months and 45% from this time last year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top